Ascelia Pharma has presented results of the Phase I study for Oncoral at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.

The poster presentation contains data from a dose escalating study in adult patients with solid tumors to assess safety, tolerability and pharmacokinetics of Oncoral, an oral irinotecan formulation, given as single agent. An abstract (# 433P) for the presentation is published online via the EMSO website (https://www.esmo.org/Conferences/ESMO-2018-Congress).